Pfizer (PFE) EBT Margin (2009 - 2026)

Pfizer has disclosed EBT Margin across 18 years of filings, most recently posting 135.53% for Q1 2026.

• In Q1 2026, EBT Margin rose 372.0% year-over-year to 135.53%; the TTM figure through Mar 2026 stood at 32.31% (down 291.0% YoY), while the FY2025 annual figure was 12.02%, down 8363.0% from the prior year.
• EBT Margin rose to 135.53% in Q1 2026, from 9.35% in the prior quarter.
• Over the last five years, EBT Margin for PFE reached as high as 1066.74% in Q3 2024 and fell as low as 203.77% in Q4 2023.
• The 5-year median for EBT Margin is 41.26% (2022), against an average of 110.41%.
• Annual changes were most pronounced in 2024 — EBT Margin soared 127051 bps — and 2025, when it slumped 92166 bps.
• A 5-year view of EBT Margin shows it stood at 39.76% in 2022, then tumbled by 402 bps to 120.24% in 2023, then surged by 987 bps to 1066.74% in 2024, then tumbled by 101 bps to 9.35% in 2025, then surged by 1549 bps to 135.53% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 135.53%, 9.35%, and 145.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.